

# BUILDING BRIDGES TO BRING ANTIAMYLOID MONOCLONAL ANTIBODIES TO ELIGIBLE PATIENTS WITH ALZHEIMER'S DISEASE

# Emergency Department Checklist for Antiamyloid Monoclonal Antibodies for Alzheimer's Disease

### Confirm antibody use:

- Ask patient or caregiver about antiamyloid therapy
- Look for ID card or wallet alert indicating:
  - Lecanemab (Leqembi<sup>®</sup>)
  - Donanemab (Kisunla<sup>®</sup>)

## Review electronic medical records and prior magnetic resonance imaging (MRI) for documentation of therapy

#### Screen for amyloid-related imaging abnormalities (ARIA) symptoms:

- Mild/moderate symptoms:
  - Headache
  - Dizziness
  - Nausea
  - Visual disturbances
  - Gait difficulty
  - Confusion
- Severe symptoms:
  - Seizures/Status epilepticus
  - Stupor or decreased responsiveness
  - Focal neurologic deficits
  - Encephalopathy

#### ✓ Imaging and radiology:

- Order unscheduled immediate MRI if ARIA suspected
- Confirm radiologist experienced with ARIA is available

#### Avoid high-risk interventions:

- Withhold tissue plasminogen activator (tPA) until ARIA is excluded (this could worsen ARIA)
- Avoid anticoagulation until ARIA has been ruled out

#### Escalation and management:

- Activate protocols to manage severe ARIA or infusion reactions, as required
- Ensure access to:
  - Neurologist familiar with ARIA, including seizures and status epilepticus
  - Monitoring and management; hospital admission if necessary
- Admit if the patient has:
  - Severe ARIA symptoms
  - Grade 3/4 infusion reaction (may require ventilatory support)
  - Ongoing neurologic concerns requiring repeat imaging or observation